Login to Your Account



Feds 'Copped Out,' Says Analyst

Roche Trial Pending, Amgen Gets CMS' Word On Payouts

By Randall Osborne


Monday, August 6, 2007
As Amgen Inc. gears up for its legal skirmish over Mircera, the erythropoietin stimulating agent (ESA) from F. Hoffmann-La Roche Ltd., the Centers for Medicare & Medicaid Services last week issued its edict on reimbursement for the class of drugs in oncology, including Amgen's and Epogen (epoetin alfa) and the second-generation product Aranesp (darbepoetin alfa). Both drugs are approved for anemia in cancer patients and in chronic kidney disease (CKD). (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription